THERAPEUTIC AREAS OF INTEREST

Cardiovascular

  • Obesity and the use of NOACs
  • Stroke Prevention in Atrial Fibrillation with NOACs
  • Dual pathway inhibition antithrombotic therapy to reduce major adverse vascular events in patients with chronic CAD and/or PAD
  • Identification of high risk medically ill patients and the role of thromboprophylaxis post discharge

Metabolism

  • Cardiovascular, Heart Failure and Renal Management in Type 2 Diabetes Mellitus with Moderate-to-Severe Renal Impairment

Neuroscience

  • Schizophrenia
  • Major Depressive Disorder (including Treatment Resistant Depression)